Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$39.31
-0.55-1.38%
Pre-Market: 5:20 AM EDT
Comments
Loading...
MoonLake Analyst Ratings and Price Targets | NASDAQ:MLTX | Benzinga
MoonLake Immunotherapeutics has a consensus price target of $65.79 based on the ratings of 17 analysts. The high is $104 issued by Oppenheimer on June 25, 2024. The low is $16 issued by Jefferies on November 11, 2022. The 3 most-recent analyst ratings were released by RBC Capital, Goldman Sachs, and HC Wainwright & Co. on March 18, 2025, February 27, 2025, and February 27, 2025, respectively. With an average price target of $80 between RBC Capital, Goldman Sachs, and HC Wainwright & Co., there's an implied 103.51% upside for MoonLake Immunotherapeutics from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Goldman Sachs
HC Wainwright & Co.
Needham
Wedbush
1calculated from analyst ratings
Analyst Ratings for MoonLake
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 70.44% | RBC Capital | Brian Abrahams52% | → $67 | Initiates | → Outperform | Get Alert |
| 02/27/2025 | Buy Now | 85.7% | Goldman Sachs | Richard Law45% | $82 → $73 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 67.9% | Needham | Serge Belanger70% | $62 → $66 | Maintains | Buy | Get Alert |
| 01/17/2025 | Buy Now | 108.6% | Goldman Sachs | Richard Law45% | $62 → $82 | Upgrade | Neutral → Buy | Get Alert |
| 01/10/2025 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 85.7% | Wedbush | Yun Zhong37% | $92 → $73 | Assumes | Outperform → Outperform | Get Alert |
| 10/15/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 09/23/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal37% | — | Reiterates | → Overweight | Get Alert |
| 09/12/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2024 | Buy Now | 57.72% | Needham | Serge Belanger70% | $62 → $62 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal37% | — | Reiterates | → Overweight | Get Alert |
| 08/26/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 08/08/2024 | Buy Now | 57.72% | Needham | Serge Belanger70% | $66 → $62 | Maintains | Buy | Get Alert |
| 07/01/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | 164.56% | Oppenheimer | Andreas Argyrides68% | → $104 | Initiates | → Outperform | Get Alert |
| 06/11/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 06/10/2024 | Buy Now | 67.9% | Needham | Serge Belanger70% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 67.9% | Needham | Serge Belanger70% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 67.9% | Needham | Serge Belanger70% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 57.72% | Goldman Sachs | Richard Law45% | → $62 | Initiates | → Neutral | Get Alert |
| 03/13/2024 | Buy Now | 134.04% | Wedbush | Andreas Argyrides68% | $92 → $92 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 134.04% | Wedbush | Andreas Argyrides68% | $92 → $92 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 67.9% | Needham | Serge Belanger70% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | 154.39% | HC Wainwright & Co. | Raghuram Selvaraju42% | $75 → $100 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 134.04% | Wedbush | Andreas Argyrides68% | $92 → $92 | Reiterates | Outperform → Outperform | Get Alert |
| 03/01/2024 | Buy Now | 67.9% | Needham | Serge Belanger70% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Initiates | → Outperform | Get Alert |
| 12/18/2023 | Buy Now | 75.53% | Stifel | Alex Thompson44% | $66 → $69 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 83.16% | Citigroup | Samantha Semenkow33% | → $72 | Initiates | → Buy | Get Alert |
| 12/01/2023 | Buy Now | 134.04% | Wedbush | Andreas Argyrides68% | → $92 | Reiterates | Outperform → Outperform | Get Alert |
| 11/27/2023 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/16/2023 | Buy Now | 134.04% | Wedbush | Andreas Argyrides68% | $86 → $92 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | 95.88% | Guggenheim | Yatin Suneja48% | $70 → $77 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 98.42% | Cantor Fitzgerald | Prakhar Agrawal37% | → $78 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 11/06/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 11/02/2023 | Buy Now | 88.25% | Stifel | Alex Thompson44% | → $74 | Initiates | → Buy | Get Alert |
| 10/16/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2023 | Buy Now | 93.34% | Needham | Serge Belanger70% | → $76 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 09/18/2023 | Buy Now | 65.35% | Cantor Fitzgerald | Prakhar Agrawal37% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 09/14/2023 | Buy Now | 65.35% | Cantor Fitzgerald | Prakhar Agrawal37% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/12/2023 | Buy Now | 50.09% | Barclays | Leon Wang67% | $41 → $59 | Maintains | Equal-Weight | Get Alert |
| 09/12/2023 | Buy Now | 65.35% | Cantor Fitzgerald | Prakhar Agrawal37% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/12/2023 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 93.34% | Needham | Serge Belanger70% | → $76 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | 93.34% | Needham | Serge Belanger70% | → $76 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 118.77% | Wedbush | Andreas Argyrides68% | $61 → $86 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 07/17/2023 | Buy Now | 90.79% | HC Wainwright & Co. | Raghuram Selvaraju42% | $37 → $75 | Maintains | Buy | Get Alert |
| 07/03/2023 | Buy Now | 65.35% | Cantor Fitzgerald | Prakhar Agrawal37% | $29 → $65 | Maintains | Overweight | Get Alert |
| 06/27/2023 | Buy Now | 4.3% | Barclays | Leon Wang67% | $28 → $41 | Maintains | Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | 65.35% | Guggenheim | Yatin Suneja48% | $51 → $65 | Maintains | Buy | Get Alert |
| 06/21/2023 | Buy Now | -5.88% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $37 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | -28.77% | Barclays | Leon Wang67% | → $28 | Initiates | → Equal-Weight | Get Alert |
| 05/15/2023 | Buy Now | -5.88% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $37 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | -5.88% | HC Wainwright & Co. | Raghuram Selvaraju42% | $30 → $37 | Reiterates | → Buy | Get Alert |
| 05/04/2023 | Buy Now | -23.68% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $30 | Reiterates | → Buy | Get Alert |
| 05/01/2023 | Buy Now | 29.74% | Guggenheim | Yatin Suneja48% | → $51 | Initiates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | -23.68% | HC Wainwright & Co. | Raghuram Selvaraju42% | $28 → $30 | Maintains | Buy | Get Alert |
| 03/22/2023 | Buy Now | -16.05% | Wedbush | Andreas Argyrides68% | → $33 | Initiates | → Outperform | Get Alert |
| 03/21/2023 | Buy Now | -28.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $28 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | -26.23% | Cantor Fitzgerald | Prakhar Agrawal37% | $23 → $29 | Maintains | Overweight | Get Alert |
| 03/09/2023 | Buy Now | -8.42% | BTIG | Julian Harrison41% | → $36 | Initiates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | -41.49% | Cantor Fitzgerald | Prakhar Agrawal37% | → $23 | Reiterates | → Overweight | Get Alert |
| 02/14/2023 | Buy Now | -41.49% | Cantor Fitzgerald | Prakhar Agrawal37% | → $23 | Initiates | → Overweight | Get Alert |
| 02/13/2023 | Buy Now | -28.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $28 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | -28.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $28 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | -59.3% | Jefferies | Kelly Shi40% | → $16 | Initiates | → Buy | Get Alert |
| 08/25/2022 | Buy Now | -56.75% | SVB Leerink | Thomas Smith33% | → $17 | Initiates | → Outperform | Get Alert |
| 07/21/2022 | Buy Now | -28.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $28 | Initiates | → Buy | Get Alert |
| 07/07/2022 | Buy Now | — | Cowen & Co. | Phil Nadeau66% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for MoonLake (MLTX) stock?
The latest price target for MoonLake (NASDAQ:MLTX) was reported by RBC Capital on March 18, 2025. The analyst firm set a price target for $67.00 expecting MLTX to rise to within 12 months (a possible 70.44% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MoonLake (MLTX)?
The latest analyst rating for MoonLake (NASDAQ:MLTX) was provided by RBC Capital, and MoonLake initiated their outperform rating.
When was the last upgrade for MoonLake (MLTX)?
The last upgrade for MoonLake Immunotherapeutics happened on January 17, 2025 when Goldman Sachs raised their price target to $82. Goldman Sachs previously had a neutral for MoonLake Immunotherapeutics.
When was the last downgrade for MoonLake (MLTX)?
The last downgrade for MoonLake Immunotherapeutics happened on August 26, 2024 when Wolfe Research changed their price target from N/A to N/A for MoonLake Immunotherapeutics.
When is the next analyst rating going to be posted or updated for MoonLake (MLTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MoonLake, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MoonLake was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating MoonLake (MLTX) correct?
While ratings are subjective and will change, the latest MoonLake (MLTX) rating was a initiated with a price target of $0.00 to $67.00. The current price MoonLake (MLTX) is trading at is $39.31, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.